View More View Less
  • 1 Bajcsy-Zsilinszky Kórház XVII. ker. Onkológiai Gondozó Budapest
  • 2 Uzsoki Utcai Kórház Fővárosi Onkoradiológiai Központ Budapest
  • 3 Uzsoki Utcai Kórház I. Belgyógyászat Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A D-vitamin aktív formája (1,25-dihidroxi-D-vitamin) saját receptorához (VDR) kapcsolódva a sejtben számos biológiai folyamatra van hatással (többek között befolyásolja az onkogének és a tumorszuppresszor gének expresszióját). A szakirodalomban egyre szaporodnak a szérum D-vitamin-szintjei, valamint a D-vitamin-pótlás és a daganatok közötti összefüggést vizsgáló közlemények. Egyes cikkek fordított arányú összefüggésre utalnak (miszerint a D-vitamin-hiányos állapot emeli a daganatos megbetegedések kockázatát és a daganatos halálozást), más közlemények viszont ezt nem támasztják alá. A kép tehát ellentmondásos. A D-vitamin számos betegség tüneteit és kimenetelét képes kedvezően befolyásolni, de a daganatos betegségekben játszott szerepe még ma sem teljesen tisztázott. Orv. Hetil., 2014, 155(28), 1091–1096.

  • Goodwin, P. J.: Vitamin D in cancer patients: above all, do no harm. J. Clin. Oncol., 2009, 27(13), 2117–2119.

  • Carlberg, C., Campbell, M. J.: Vitamin D receptor signaling mechanisms: Integrated actions of a well-defined transcription factor. Steroids, 2013, 78(2), 127–136.

  • Guo, J., Liu, Z. S.: Multiple effects of vitamin D. Chin. Med. J., 2013, 126(15), 2978–2983.

  • Welsh, J.: Cellular and molecular effects of vitamin D on carcinogenesis. Arch. Biochem. Biophys., 2012, 523(1), 107–114.

  • Lakatos, P., Speer, G.: Vitamin D: biological and clinical effects. [A D-vitamin biológiai és klinikai hatásai.] Lege Artis Medicinae, 2002, 12(1), 8–17. [Hungarian]

  • Speer, G.: The D-day. The role of vitamin D in the prevention and the additional therapy of cancers. [A D-nap. A D-vitamin helye a daganatprevencióban és a kiegészítő kezelésben.] Magy. Onkol., 2010, 54(4), 303–314. [Hungarian]

  • Stambolsky, P., Tabach, Y., Fontemaggi, G., et al.: Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell, 2010, 17(3), 273–285.

  • Pino, A. M., Rodríguez, J. M., Ríos, S., et al.: Aromatase activity of human mesenchymal stem cells is stimulated by early differentation, vitamin D and leptin. J. Endocrinol., 2006, 191(3), 715–725.

  • Dizdar, O., Bulut, N., Altundag, K.: Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer. Breast, 2008, 17(2), 120.

  • Ahn, J., Peters, U., Albanes, D., et al.: Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J. Natl. Cancer Inst., 2008, 100(11), 796–804.

  • Pande, M., Thompson, P. A., Do, K-A., et al.: Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis, 2013, 34(3), 587–594.

  • Ross, A. C., Manson, J. E., Abrams, S. A., et al.: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab., 2011, 96(1), 53–58.

  • Goodwin, P. J., Ennis, M., Pritchard, K. I., et al.: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol., 2009, 27(23), 3757–3763.

  • Clark, A. S., Chen, J., Kapoor, S., et al., and I-SPY TRIAL-1 Investigators: Pretreatment vitamin D levels and response to neoadjuvant chemotherapy in the I-SPY 1 TRIAL. Cancer Res., 2012, 72(24 Suppl. 3), Abstract P3-06-10.

  • Coleman, R. E., Rathborne, E. J., Marshall, H. C., et al.: Vitamind D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Cancer Res., 2012, 72(24 Suppl. 3), Abstract S6-4.

  • Hatse, S., Lambrechts, D., Verstuyf, A., et al.: Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis, 2012, 33(7), 1319–1326.

  • Tretli, S., Schwartz, G. G., Torjesen, P. A., et al.: Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of the breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control, 2012, 23(2), 363–370.

  • Villaseñor, A., Ballard-Barbash, R., Ambs, A., et al: Association of serum 25-hydroxyvitamin D with overall and breast cancer-specific mortality in a multiethnic cohort of breast cancer survivors. Cancer Causes Control, 2013, 24(4), 759–767.

  • Vrieling, A., Hein, R., Abbas, S., et al.: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res., 2011, 13(4), R74.

  • Rose, A. A., Elser, C., Ennis, M., et al.: Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. Breast Cancer Res. Treat., 2013, 141(3), 331–339.

  • Fedirko, V., Torres-Mejía, G., Ortega-Olvera, C., et al.: Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control, 2012, 23(7), 1149–1162.

  • Wang, D., Vélez de-la-Paz, O. I., Zhai, J. X., et al.: Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumor Biol., 2013, 34(6), 3509–3517.

  • Bauer, S. R., Hankinson, S. E., Bertone-Johnson, E. R., et al.: Plasma vitamin D levels: menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore), 2013, 92(3), 123–131.

  • Peppone, L. J., Rickles, A. S., Janelsins, M. C., et al.: The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann. Surg. Oncol., 2012, 19(8), 2590–2599.

  • Piura, E., Chapman, J. W., Lipton, A., et al.: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J. Clin. Oncol., 2009, 27(155-May 20), Abstract 15S, 534.

  • Eliassen, A. H., Spiegelman, D., Hollis, B. W., et al.: Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res., 2011, 13(3), R50.

  • Yin, L., Grandi, N., Raum, E., et al.: Meta-analysis: serum vitamin D and breast cancer risk. Eur. J. Cancer, 2010, 46(12), 2196–2205.

  • Cauley, J. A., Chlebowski, R. T., Wactawski-Wende, J., et al.: Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women’s Health Initiative. J. Women’s Health, 2013, 22(11), 915–929.

  • Bolland, M. J., Grey, A., Gamble, G. D., et al.: The effect of vitamin D supplementation on skeletal, vascular or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol., 2014, 2(4), 307–320.

  • Manson, J. E., Bassuk, S. S., Lee, I. M., et al.: The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials, 2012, 33(1), 159–171.

  • Lawrence, J. A., Akman, S. A., Melin, S. A., et al.: Oral paricalcitol (19-nor-1,25-dihyxdroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol. Ther., 2013, 14(6), 476–480.

  • Buttigliero, C., Monagheddu, C., Petroni, P., et al.: Prognostic role of vitamin D status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist, 2011, 16(9), 1215–1227.

  • Sperati, F., Vici, P., Maugeri-Saccá, M., et al.: Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE, 2013, 8(7), e69269.